Pfizer Specialty Care strives to deliver breakthroughs that enable freedom from day-to-day suffering for people living with chronic inflammatory diseases, which can be debilitating, disfiguring, and distressing. LITFULO, one of Pfizer’s 25 by 25 launches, is a JAK3/TEC molecule that received approval in June 2023 and is the first and only FDA-approved treatment for severe AA in adolescents (ages 12-17) and adults. Currently, there are three FDA-approved medicines for adults with severe AA, with new competitors entering the market starting mid-2026. The US LITFULO team comprises a group of talented, diverse, tenacious colleagues and attracts employees focused on developing or enhancing their growth mindset. With several Pfizer Firsts under our belt, we remain focused on building an excellent, innovative brand with patients at the center of our mission. The team is driven by an unrelenting determination to embody Pfizer’s values and to be the catalyst for every team member’s success. We harness our individual and collective strengths and embrace the courage to pursue boldness.